POAI Predictive Oncology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: POAI

Price (delayed)

$1.81

Market cap

$7.35M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.48

Enterprise value

$1.48M

Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data ...

Highlights
The EPS has soared by 50% YoY and by 25% from the previous quarter
POAI's net income is up by 46% year-on-year and by 24% since the previous quarter
POAI's gross profit is up by 14% year-on-year but it is down by 10% since the previous quarter
Predictive Oncology's equity has shrunk by 62% YoY and by 29% QoQ
Predictive Oncology's quick ratio has shrunk by 60% YoY and by 23% QoQ
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.precisiontherapeutics.com
Peers: NVRO OFIX NURO

Key stats

What are the main financial stats of POAI
Market
Shares outstanding
4.06M
Market cap
$7.35M
Enterprise value
$1.48M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.89
Price to sales (P/S)
4.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.83
Earnings
Revenue
$1.78M
EBIT
-$13.98M
EBITDA
-$13.24M
Free cash flow
-$13.47M
Per share
EPS
-$3.48
Free cash flow per share
-$3.35
Book value per share
$2.04
Revenue per share
$0.44
TBVPS
$3.53
Balance sheet
Total assets
$14.42M
Total liabilities
$6.15M
Debt
$2.86M
Equity
$8.27M
Working capital
$6.13M
Liquidity
Debt to equity
0.35
Current ratio
2.55
Quick ratio
2.29
Net debt/EBITDA
0.44
Margins
EBITDA margin
-744%
Gross margin
64.3%
Net margin
-785.6%
Operating margin
-794.9%
Efficiency
Return on assets
-71.2%
Return on equity
-105.2%
Return on invested capital
-283%
Return on capital employed
-133.6%
Return on sales
-785.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

POAI stock price

How has the Predictive Oncology stock price performed over time
Intraday
6.47%
1 week
16.77%
1 month
-8.12%
1 year
-42.54%
YTD
-44.98%
QTD
-29.02%

Financial performance

How have Predictive Oncology's revenue and profit performed over time
Revenue
$1.78M
Gross profit
$1.15M
Operating income
-$14.15M
Net income
-$13.98M
Gross margin
64.3%
Net margin
-785.6%
The company's net margin has surged by 54% YoY and by 23% QoQ
POAI's operating margin has soared by 54% year-on-year and by 23% since the previous quarter
POAI's operating income is up by 46% YoY and by 24% QoQ
POAI's net income is up by 46% year-on-year and by 24% since the previous quarter

Growth

What is Predictive Oncology's growth rate over time

Valuation

What is Predictive Oncology stock price valuation
P/E
N/A
P/B
0.89
P/S
4.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.83
The EPS has soared by 50% YoY and by 25% from the previous quarter
Predictive Oncology's equity has shrunk by 62% YoY and by 29% QoQ
The price to book (P/B) is 36% less than the 5-year quarterly average of 1.4 and 36% less than the last 4 quarters average of 1.4
The P/S is 81% lower than the 5-year quarterly average of 21.1 and 64% lower than the last 4 quarters average of 11.3
POAI's revenue is up by 18% YoY

Efficiency

How efficient is Predictive Oncology business performance
Predictive Oncology's ROIC has soared by 86% YoY and by 42% from the previous quarter
The ROS has soared by 54% YoY and by 23% from the previous quarter
The company's return on equity fell by 25% YoY but it rose by 4.8% QoQ
The return on assets rose by 13% since the previous quarter and by 6% year-on-year

Dividends

What is POAI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for POAI.

Financial health

How did Predictive Oncology financials performed over time
The company's total assets is 135% higher than its total liabilities
Predictive Oncology's quick ratio has shrunk by 60% YoY and by 23% QoQ
The current ratio has dropped by 58% year-on-year and by 21% since the previous quarter
The company's debt is 65% lower than its equity
Predictive Oncology's equity has shrunk by 62% YoY and by 29% QoQ
The debt to equity has grown by 30% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.